Concepedia

Publication | Closed Access

Cost‐effectiveness of respiratory syncytial virus prophylaxis with palivizumab

DOI

43

Citations

21

References

2006

Year

Carole Reeve, John Whitehall, Petra Buettner, Robert Norton, David Mark Reeve, Fleur Francis
Journal of Paediatrics and Child Health

Abstract

Palivizumab was not cost-effective in the prophylaxis of RSV in the high-risk group of infants tested here.

References

YearCitations

Page 1